改良PCH方案用于人表皮样生长因子受体2阳性局部晚期女性乳腺癌的临床研究

Abstract
Figure/Table
References (28)
Related Citation (15)

Download: PDF (641 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the clinical efficacy of modified PCH regimen (Trastuzumab+Paclitaxel+Carboplatin) for locally advanced female breast cancer with positive human epidermal growth factor receptor 2 (HER-2). Methods A total of 134 patients with locally advanced female breast cancer with positive HER-2 admitted to Binhai People’s Hospital Affiliated to Kangda College of Nanjing Medical University were selected, they were divided into observation group and control group by random number table method, with 67 cases in each group. The control group received Paclitaxel and Carboplatin, and the observation group received modified PCH regimen. After chemotherapy, both groups received modified radical mastectomy for breast cancer. The clinical efficacy of two groups was observed; serum tissue polypeptide specific antigen (TPS) and carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), CD3+, CD4+, CD8+, and CD4+/CD8+ were detected before treatment and six months after treatment; the incidence of adverse reactions in two groups was recorded. Results The disease control rate in observation group was higher than that in control group (P ＜ 0.05). Six months after treatment, the levels of TPS, CEA, and CA125 in both groups were lower than those before treatment, and observation group was lower than control group (P < 0.05). Six months after treatment, CD3+, CD4+, and CD4+/CD8+ in both groups were decreased compared with before treatment (P < 0.05); there was no significant difference in CD8+ levels between two groups (P > 0.05). Six months after treatment, there were no significant differences in CD3+, CD4+, CD8+, and CD4+/CD8+ between two groups (P > 0.05). The total incidence of adverse reactions in observation group was lower than that in control group (P < 0.05). Conclusion Modified PCH regimen has a good efficacy for locally advanced female breast cancer with positive HER-2, which can reduce serum tumor marker level and is not likely to damage immune function, with high safety.

Key words： Breast cancer Chemotherapy Tumor markers Immune function Adverse reactions

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Minglei1 ZHENG Shiya2 HOU Bo1 LI Haiyang1 YIN Xiaodong1▲

Cite this article:

ZHANG Minglei1 ZHENG Shiya2 HOU Bo1 LI Haiyang1 YIN Xiaodong1▲. Clinical study of modified PCH regimen for locally advanced breast cancer with positive human epidermal growth factor receptor 2 #br#[J]. 中国医药导报, 2022, 19(11): 127-130.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I11/127

[1] Filipova A，Seifrtova M，Mokry J，et al. Breast Cancer and Cancer Stem Cells：A Mini-Review [J]. Tumori，2014，100（4）：363-369.
[2] Marmot MG，Altman DG，Cameron DA，et al. The benefits and harms of breast cancer screening：an independent review [J]. Lancet，2013，381（9855）：2205-2240.
[3] Lautrup MD，Thorup SS，Jensen V，et al. Male breast cancer：a nation-wide population-based comparison with female breast cancer [J]. Acta Oncol，2017，57（5）：613-621.
[4] 王雪，袁芃.奈拉替尼在激素受体阳性人表皮生长因子受体2阳性乳腺癌治疗中的应用[J].中华肿瘤杂志，2021， 43（5）：511-515.
[5] 骆艺，黄剑.ER-α36介导乳腺癌中曲妥珠单抗耐药的新机制[J].医学综述，2021，27（9）：1722-1727.
[6] 周守兵，刘宇，刘虎，等.吡咯替尼联合化疗在曲妥珠单抗耐药乳腺癌肝转移患者中的疗效[J].安徽医学，2020， 41（1）：33-35.
[7] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范（2008版）[J].中国癌症杂志，2009，19（6）：448-474.
[8] Spinelli JB，Yoon H，Ringel AE，et al. Metabolic recycling of ammonia via glutamate dehydrogenase supports breast cancer biomass [J]. Science，2017，358（6365）：941-946.
[9] 李贝贝，杨婷婷，关萌，等.HR+HER2-晚期乳腺癌内分泌治疗临床应用的研究进展[J].吉林大学学报（医学版），2019，45（3）：736-741.
[10] 徐巧萍，朱洁瑾，刘坚，等.HER-2阳性乳腺癌患者2种新辅助化疗方案的药物经济学评价[J].中国现代应用药学，2019，36（8）：89-96.
[11] 伍雁琦，罗婷.激素受体/人表皮生长因子受体2阳性乳腺癌治疗研究进展[J].中国全科医学，2021，24（8）：1028-1032，1036.
[12] 辛灵，张虹，张爽，等.多西他赛+卡铂联合曲妥珠单抗方案对早期人表皮生长因子受体2阳性乳腺癌的新辅助治疗效果[J].中华外科杂志，2021，59（3）：222-227.
[13] 韩逸群，樊英，陈闪闪，等.跨线曲妥珠单抗治疗HER2阳性乳腺癌疗效分析[J].临床药物治疗杂志，2019，17（6）：71-75.
[14] 王利锋，马艳飞，李小峰.曲妥珠单抗和拉帕替尼治疗早期HER2过表达型乳腺癌患者的有效性分析[J].国际外科学杂志，2019，46（5）：321-325.
[15] 郑向欣，吴骥，顾书成，等.首诊HER-2阳性局部晚期年轻乳腺癌行改良PCH方案新辅助治疗的临床观察[J].中国普通外科杂志，2020，29（11）：1311-1318.
[16] 欧开萍，李俏，罗扬，等.阿帕替尼联合紫杉醇和卡铂密集方案新辅助治疗三阴性乳腺癌的近期疗效及安全性[J].中华肿瘤杂志，2020，42（11）：966-971.
[17] 张晓宇，张辉，杨云云，等.曲妥珠单抗联合紫杉醇、卡铂新辅助化疗治疗HER-2阳性乳腺癌的效果观察及对心功能、近期预后的影响[J].临床误诊误治，2019，32（10）：51-56.
[18] 沈春燕，金晓新，王淑玲.曲妥珠单抗联合GEM、CAP化疗对HER-2阳性晚期乳腺癌患者血清T细胞亚群、TPS水平及生存质量的影响[J].中国医药导报，2019， 16（19）：93-97.
[19] 徐晓敏，董琳，崔金芳，等.多西紫杉醇联合卡铂或卡培他滨一线治疗乳腺癌肺转移的疗效对比[J].现代肿瘤医学，2020，28（23）：73-77.
[20] 梅林，许扬，徐少华，等.卡培他滨治疗对HER-2阳性乳腺癌患者肿瘤标志物，抑癌基因表达及心肌损伤的影响[J].川北医学院学报，2020，35（2）：317-320.
[21] 赵敏，戴成燕，丁平，等.曲妥珠单抗联合TC化疗对HER-2阳性晚期乳腺癌外周血及预后影响[J].现代肿瘤医学，2020，28（14）：2431-2435.
[22] 张至惠，胡述博，王志峰，等.补肾活血汤联合曲妥珠单抗治疗Her-2阳性晚期乳腺癌临床疗效及对患者免疫功能的影响[J].世界中医药，2019，14（4）：993-996.
[23] 周金妹，胡晓，张会强，等.曲妥珠单抗联合蒽环类药物对HER2阳性乳腺癌患者心脏功能影响临床观察[J].中华肿瘤防治杂志，2019，26（10）：707-712.
[24] 沈永康，张美华，陈文婷.曲妥珠单抗联合新辅助化疗治疗HER-2过表达乳腺癌的临床研究[J].中国医药科学，2020，10（6）：69-72.
[25] 李剑，赵二保，畅俊平.新辅助化疗联合曲妥珠单抗对HER-2过表达乳腺癌的疗效观察及对肿瘤因子的影响[J].中国药物与临床，2019，19（16）：2801-2803.
[26] 董懿，王钢乐，曹技磊.曲妥珠单抗联合新辅助化疗治疗HER2阳性乳腺癌的临床疗效及对患者生存质量的影响[J].癌症进展，2019，17（19）：73-75.
[27] 甄洪超，李琴，杜琪，等.曲妥珠单抗辅助治疗对HER2阳性晚期乳腺癌安全性的Meta分析[J].临床和实验医学杂志，2020，19（1）：43-47.
[28] 龚玉爱，舒诚荣，韩琦.曲妥珠单抗联合化疗在接受改良根治术并行术后化疗初治乳腺癌患者中的应用[J].中国当代医药，2020，27（22）：83-86.